Contineum Therapeutics (CTNM) Common Equity (2023 - 2025)
Historic Common Equity for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $180.5 million.
- Contineum Therapeutics' Common Equity fell 1415.51% to $180.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.5 million, marking a year-over-year decrease of 1415.51%. This contributed to the annual value of $198.1 million for FY2024, which is 39154.79% up from last year.
- Contineum Therapeutics' Common Equity amounted to $180.5 million in Q3 2025, which was down 1415.51% from $171.4 million recorded in Q2 2025.
- Contineum Therapeutics' 5-year Common Equity high stood at $217.5 million for Q2 2024, and its period low was -$75.6 million during Q1 2024.
- Its 3-year average for Common Equity is $127.4 million, with a median of $182.6 million in 2025.
- As far as peak fluctuations go, Contineum Therapeutics' Common Equity skyrocketed by 39154.79% in 2024, and later crashed by 2120.11% in 2025.
- Contineum Therapeutics' Common Equity (Quarter) stood at -$67.9 million in 2023, then surged by 391.55% to $198.1 million in 2024, then decreased by 8.88% to $180.5 million in 2025.
- Its Common Equity was $180.5 million in Q3 2025, compared to $171.4 million in Q2 2025 and $184.8 million in Q1 2025.